An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations

Trial Profile

An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs AGTC-501 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 18 Apr 2018 According to an Applied Genetic Technologies Corporation media release, first patient has been dosed.
    • 09 Feb 2018 According to an Applied Genetic Technologies Corporation media release, the company is currently screening patients and two out of five sites are now open for enrollment.
    • 02 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top